Background: Urinary symptoms are common, disabling and generally unresponsive to treatment in Parkinson´s disease (PD). Safinamide is approved as an add-on therapy to levodopa to improve fluctuations. Methods: Retrospective analysis of electronic records of nondemented PD patients seen consecutively in a Movement Disorders Unit (November 2018–February 2019). All were assessed with Scale for Outcomes in Parkinson’s disease for Autonomic Symptoms-Urinary subscale (SCOPA-AUT-U) by the attending neurologist, and a month afterwards by an independent researcher blinded to treatment and clinical records in a routine clinical practice setting. Clinical variables were compared among patients who were prescribed safinamide (SA+) for the treatment of motor fluctuations and those with different treatment regimes (SA−). Results: From 169 patients screened initially, 54 were excluded due to severe incontinence, absence of urinary symptoms or previous safinamide treatment. Thirty-five patients were included in SA+ and 79 in SA−. Both groups were comparable in terms of clinical variables, except in basal urinary symptoms, with more severity in the SA+ group. In the follow-up assessment, total SCOPA-AUT-U, as well as urgency, incontinence, frequency and nocturia subscales improved significantly in the SA+ group, while the SA− group remained unchanged. Conclusions: Safinamide could be helpful in the improvement of urinary symptoms in PD.

中文翻译：

---

SURINPARK：沙芬酰胺治疗帕金森病的泌尿系统症状


背景：泌尿系统症状在帕金森病 (PD) 中很常见、致残且通常对治疗无反应。沙芬酰胺被批准作为左旋多巴的附加疗法，以改善波动。方法：对运动障碍科室连续就诊的非痴呆 PD 患者（2018 年 11 月至 2019 年 2 月）的电子记录进行回顾性分析。所有患者均由主治神经科医生使用帕金森病自主神经症状结果量表 - 泌尿分量表 (SCOPA-AUT-U) 进行评估，一个月后由一位对常规临床实践中的治疗和临床记录不知情的独立研究人员进行评估。对服用沙芬酰胺（SA+）治疗运动波动的患者和采用不同治疗方案（SA−）的患者的临床变量进行了比较。结果：在最初筛查的 169 名患者中，有 54 名因严重失禁、没有泌尿系统症状或既往接受过沙芬酰胺治疗而被排除。 35 名患者被纳入 SA+，79 名患者被纳入 SA−。除了基础泌尿症状外，两组的临床变量具有可比性，SA+组的严重程度更高。在后续评估中，SA+组的总SCOPA-AUT-U以及尿急、尿失禁、尿频和夜尿量表均显着改善，而SA−组则保持不变。结论：沙芬酰胺有助于改善帕金森病的泌尿系统症状。